Video: Yaz and Yasmin Birth Control Again Linked to Blood Clots in FDA Study


In the video above, Jessica Vertullo from the national law firm of Parker Waichman LLP discusses the risks of using Yaz or Yasmin birth control pills. These oral contraceptives have already been associated with an increased risk of blood clots in the past, but now there is even more evidence linking Yaz and Yasmin to blood clots in the veins and arteries. According to a study funded by the U.S. Food and Drug Administration (FDA), women taking birth control pills such as Yaz or Yasmin are 77 percent more likely to experience venous thromboembolic events (VTE) and arterial thromboembolic events. The study was published in September issue of Contraception journal.

Yaz and Yasmin are thought to increase the risk of blood clots because they contain the synthetic hormone drospirenone. In April, the FDA updated the safety label on Yaz, Yasmin  and other oral contraceptives containing drospirenone to warn about this risk. According to the new safety information, some studies show that women who take drospirenone-based birth control are three times as likely to develop blood clots. Blood clots associated with the use of Yaz and Yasmin can manifest as deep vein thrombosis (DVT), which is a clot that forms in the deep veins of the leg. A part of this clot can break off and become lodge elsewhere, such as the lungs, brain or heart; this is known as an embolism, and can be potentially fatal.